MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent
Law360 (May 13, 2020, 3:53 PM EDT) -- The Patent Trial and Appeal Board will review whether claims of a Merck patent covering the blockbuster diabetes drugs Januvia and Janumet are invalid, shooting down a variety of arguments from the drugmaker that the board should use its discretion to deny Mylan's petition.
When instituting review Tuesday, the board said it wasn't persuaded by Merck Sharp & Dohme Corp.'s arguments that an inter partes review would leave the company at a disadvantage in related multidistrict litigation, where it's accusing Mylan and other generic-drug makers of infringement. Merck also failed to show that the U.S. Patent and Trademark Office examiner already...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!